Why the Skin Under Your Eyes Changes After Menopause: What the Research Shows

• Why does the skin under your eyes look different after menopause?
• How thin is the skin under your eyes, really?
• What does menopause do to blood flow in that specific area?
• What does shilajit's own research show about this same signal?
• Is under-eye darkness really just one thing?
• How does this compare with what usually gets tried first?
• Common questions about under-eye skin and shilajit

Why does the skin under your eyes look different after menopause?

Most women can point to roughly when the skin under their eyes started reading differently, tired even after a full night's sleep, hollow in a way concealer stopped covering. That is not in your head, and it is not really about sleep at all.

Shilajit and its active compound, fulvic acid, have real human research behind the same tissue signal this article traces, collagen production and skin blood flow. That research did not set out to study dark circles. It studied what happens to skin structure and circulation when shilajit is taken, and it happens to land on the exact two systems that make the skin under your eyes change shape and color after menopause.

Two systems, one shared cause

Skin needs two things to stay resilient. It needs collagen, the structural protein that holds tissue together, and it needs blood vessels that keep circulating close to the surface. Both of those systems run partly on estrogen. When estrogen falls at menopause, both weaken at close to the same time, and nowhere on the body is that combination more visible than the thinnest skin you have.

How thin is the skin under your eyes, really?

This is not a guess. Researchers have actually measured it, across the body, in real tissue.

Lee and colleagues (2002) took 452 skin biopsies across 28 different body regions in adult subjects and measured epidermis and dermis thickness under a microscope. Eyelid skin came in at roughly 521 to 626 microns, among the thinnest of every site tested. Skin on the back, by comparison, measured nearly 1,977 microns, more than three times thicker.

A separate cadaver study by Hwang and colleagues (2006) dissected the eyelid specifically and found the thinnest point sits right near the lash line, at roughly 320 microns, rising to over 1,100 microns just below the eyebrow.

Those numbers come from two separate studies using two separate methods, biopsy and cadaver dissection, and they land in the same range. That consistency is exactly why dermatology treats the eyelid as a distinct case rather than typical facial skin.

Why thin skin shows more of what is underneath it

Skin this thin does not fully hide the tissue beneath it. Blood vessels sit close enough to the surface that their color shows through, the way a thin curtain shows the shape of what is behind it rather than blocking it out. That single fact is most of the explanation for why this specific area darkens differently than the rest of the face.

What does menopause do to blood flow in that specific area?

Thin skin is only half the story. The other half is what is moving underneath it, and menopause changes that too.

Sherman and colleagues (1998) measured microvascular blood flow response in three groups, premenopausal women, postmenopausal women, and postmenopausal women on hormone replacement therapy. Using a standard vasodilator test, premenopausal women showed a 187% increase in blood flow response. Postmenopausal women showed 93%, roughly half. Women on hormone therapy showed 142%, a partial recovery.

• Estrogen decline is linked to roughly half the microvascular responsiveness measured before menopause
• Hormone therapy partly restored that response in the same study, which supports estrogen as the driver, not a coincidence
• A separate review by Calleja-Agius and Brincat (2007) put it plainly, describing "a strong correlation between skin collagen loss and estrogen deficiency due to the menopause"
• A controlled study by Chotnopparatpattara and colleagues (2001) found combined estrogen-progestin therapy produced a statistically significant increase in skin thickness over 24 weeks, versus a calcium-only comparison group

Slower blood flow shows up as color. Blood that moves normally stays bright. Blood that pools or moves sluggishly through smaller, less responsive vessels reads darker under skin this thin, which is a mechanical explanation, not a guess about what you are seeing in the mirror.

What does shilajit's own research show about this same signal?

Shilajit's human research was not designed around the eye area. It was designed around exactly the two systems described above, skin blood flow and collagen gene activity, tested directly in adult women.

Das and colleagues (2019) ran a 14-week trial in healthy middle-aged women, giving shilajit at 125 or 250 milligrams twice daily, then took skin biopsies and used gene-expression sequencing alongside dermascopic perfusion imaging. At the 250-milligram dose, shilajit improved measured skin perfusion compared to baseline and to placebo, and it induced genes tied to blood-vessel growth and extracellular matrix repair. No adverse effects were reported over the 14 weeks.

A separate 8-week trial by Das and colleagues (2016) gave adults 500 milligrams of shilajit daily and biopsied tissue directly. The result was a cluster of 17 collagen and extracellular-matrix genes turned up, with the strongest single gene rising more than fivefold above baseline.

Not a hormone, and not a claim about dark circles

Shilajit is not estrogen and does not add estrogen to the body. What the research shows is support for the body's own estrogen signaling, the same signal that Sherman's team found weakens blood flow response by roughly half after menopause. That is a mechanism finding, not an outcome trial. No study has measured whether shilajit changes how dark or hollow the under-eye area looks, and it would be overclaiming to say otherwise.

Is under-eye darkness really just one thing?

No, and the dermatology literature says so directly. A 2023 clinical review classified periorbital darkness into four subtypes, pigmented, vascular, structural, and mixed, and noted that treatment depends on identifying which one applies. A separate 2021 systematic review reached the same four-part classification independently.

• Pigmentation from excess melanin is one recognized cause, separate from thin skin or blood flow
• Structural volume loss, hollowing beneath the eye, is another, and it is addressed differently than a vascular cause
• Sleep disruption, allergies, and genetics are all listed as real, documented contributors in a 2014 review of the condition
• That same review notes the appearance "usually progresses over time" without intervention, which is a separate finding from anything about cause

It is also worth being direct about who this research was studied in. One widely cited review notes the condition is most commonly described in women aged 16 to 45, a population considerably younger than a postmenopausal woman. The mechanism in this article, thin skin plus reduced estrogen-linked blood flow, is specific to what changes after menopause. It does not claim to be the only explanation for every woman's experience with this, and we are stating that plainly rather than implying one tidy cause.

How does this compare with what usually gets tried first?

Most of what gets reached for first works from the outside of the problem.

None of these approaches is wrong for what it targets. Covering color and adding volume solve real, different problems. The research in this article sits underneath all of them, at the level of the tissue itself, and it comes with the same honest limit stated throughout, no trial has measured the visible outcome directly.

Shilajit's fulvic acid content is the mechanism behind the collagen and perfusion research described above, sourced from the Altai mountains and paired with pearl powder and bamboo silica in the Optimum Shilajit Trifecta, third-party lab tested for purity on every batch. No study has tested it against under-eye appearance specifically, and we say that plainly rather than imply a result the research has not shown.